Velan (VLN) EGM 2025 summary
Event summary combining transcript, slides, and related documents.
EGM 2025 summary
26 Dec, 2025Opening remarks and agenda
Meeting called to order by the Chair, conducted virtually to ensure equal participation for all shareholders.
Rules for orderly conduct, language options, and voting procedures explained at the outset.
Specific resolutions to be voted on
Special resolution to approve the sale of all shares in Segault SAS and Velan SAS, French subsidiaries, to Framatome for $177.6 million, plus an intercompany loan, totaling $201.1 million.
Full transaction details and resolution text provided in the Management Information Circular and its appendix.
Corporate governance
Voting rights clarified: each subordinate and multiple voting share carries five votes; only shareholders of record as of February 24, 2025, may vote.
Quorum confirmed with at least 10% of eligible votes represented.
Scrutineers from TSX Trust Company appointed to tabulate votes and certify results.
Latest events from Velan
- Bookings and backlog improved, supporting growth and cash flow focus for 2025.VLN
AGM 20243 Feb 2026 - Q1 sales up 14.5%, gross margin 30.7%, backlog $528.3M, and major nuclear deal signed.VLN
Q1 20253 Feb 2026 - Bookings and sales soared, backlog reached $548.1M, and net income turned positive.VLN
Q2 202519 Jan 2026 - Strong backlog, major asset sale, and ownership transition marked Q3 2026.VLN
Q3 202615 Jan 2026 - Q3 saw 18.1% sales growth, margin gains, and risk reduction from major divestitures.VLN
Q3 202510 Jan 2026 - Sales and margins surged, with divestitures and a special dividend boosting future prospects.VLN
Q4 202524 Nov 2025 - 18.6% sales growth, margin gains, and record cash drive a higher dividend and strong outlook.VLN
Q1 202616 Nov 2025 - Strong growth, risk reduction, and strategic expansion defined the year, with all motions approved.VLN
AGM 202516 Nov 2025 - Q2 sales fell 13%, but backlog and liquidity rose, supporting growth in key sectors.VLN
Q2 202612 Oct 2025